Moreover, blockade of LFA-1 with an anti-LFA-1 mAb reduced the already ongoing inflammation, and functional blockade of its counter-receptors, ICAM-1, ICAM-2, and JAM-A, provided a reduction, but not complete amelioration, of arthritis (77). Here, ITGAL is linked to arthritic joint disease.